WANG-DA LIUPang, Man WaiMan WaiPangJANN-TAY WANGHSIN-YUN SUNYU-SHAN HUANGKUAN-YIN LINUN-IN WULi, Guei-ChiGuei-ChiLiLiu, Wen-ChunWen-ChunLiuSu, Yi-ChingYi-ChingSuHe, Pu-ChiPu-ChiHeLin, Chia-YiChia-YiLinYeh, Chih-YuChih-YuYehCheng, Yu-ChenYu-ChenChengYao, YiYiYaoChen, Yi-TingYi-TingChenWu, Pei-YingPei-YingWuChen, Ling-YaLing-YaChenLuo, Yu-ZhenYu-ZhenLuoChang, Hsi-YenHsi-YenChangWANG-HUEI SHENGSZU-MIN HSIEHSUI-YUAN CHANGCHIEN-CHING HUNGSHAN-CHWEN CHANG2023-01-182023-01-1820222055-6640https://scholars.lib.ntu.edu.tw/handle/123456789/627450A community COVID-19 outbreak caused by the B.1.1.7 SARS-CoV-2 variant occurred in Taiwan in May 2021. High-risk populations such as people living with HIV (PLWH) were recommended to receive two doses of COVID-19 vaccines. While SARS-CoV-2 vaccines have demonstrated promising results in general population, real-world information on the serological responses remains limited among PLWH.enAntibody; BNT162b2 vaccine; ChAdOx1 nCoV-19 (AZD1222) vaccine; Humoral immunity; mRNA-1273 vaccine[SDGs]SDG3journal article10.1016/j.jve.2022.100308365310822-s2.0-85144431638WOS:000906235500001https://api.elsevier.com/content/abstract/scopus_id/85144431638